Skip to content
Screener

Palvella Therapeutics PVLA EBITDA

EBITDA at other companies

Relay Therapeutics, Inc. logo
Relay Therapeutics, Inc.RLAY
-$90.46M-19.3%
Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN
-$126.15M-18.3%
ANI Pharmaceuticals logo
ANI PharmaceuticalsANIP
$60.1M+61.7%
Arcutis Biotherapeutics, Inc. logo
Arcutis Biotherapeutics, Inc.ARQT
$16.99M+221%
Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
$17.14M+125%
Eton Pharmaceuticals, Inc. logo
Eton Pharmaceuticals, Inc.ETON
$3.55M+553%

Other financials

Income statement

See full
Revenue$53.0K-97.3%
Operating income-$14.9M-88.7%
Net income-$15.8M-92.6%
EPS (diluted)-$1.20-62.2%

Balance sheet

See full
Cash & equivalents$206.4M+173%
Total debt$584.0K—
Total equity$232.3M+318%
Total assets$263.8M+232%

Cash flow

See full
Operating cash flow-$10.9M-60.5%
CapEx--100%
Free cash flow-$2.7M+72.0%

Valuation

See full
Market cap$2.23B+417%
Enterprise value$2.03B—

Profitability

See full
Operating margin-183.2%—
Net margin71.7%+40.4pp
FCF margin-99.8%-34.2pp

Returns & leverage

See full
Return on equity-34.2%—
Debt / equity0×—
Current ratio28.9×+20.0×

Where this comes from

Calculated from Palvella Therapeutics’s reported figures.

−$1.8Mebit−
$30.0KDepreciation Depletion & Amortization
=-$1.79M

The source filing: Palvella Therapeutics’s 10-K, filed March 31, 2026. Open the filing →

Filed
Mar 31, 2026, 8:30 AM EDT
Fiscal year
FY2025
Accession
0001193125-26-133372

FAQ

What is Palvella Therapeutics's EBITDA?
Palvella Therapeutics (PVLA) reported EBITDA of -$1.79M in Q1 2024.
What does EBITDA mean?
Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.

Ask your AI about Palvella Therapeutics's ebitda.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude